EVALUATION OF THE EFFICACY OF IMIDAZOLINE RECEPTOR AGONISTS IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
Abstract
Objective: To evaluate the antihypertensive, metabolic, and sympatholytic efficacy of imidazoline receptor agonists (IRAs)—moxonidine and rilmenidine—in patients with arterial hypertension (AH) and metabolic syndrome (MS).
References
1. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. Metabolic effects of moxonidine and amlodipine in obese hypertensive patients. Am J Hypertens. 2007;20(12):1333–1339.
2. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976–990.
3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112(17):2735–2752.
4. Haller H, Hanefeld M, Partner A, et al. Moxonidine reduces insulin resistance in hypertensive patients. J Hypertens. 1997;15(5):561–568.
5. Julià P, Redon J, Pascual JM, et al. Long-term effects of moxonidine on metabolic control. Am J Hypertens. 2004;17(7):569–573.
6. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. Am J Hypertens. 1996;9(2):113S–120S.
7. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.
8. Khalmetova, Feruza; Akhmedov, Khalmurad; Tavasharov, Bahodir; Razakova, Feruza. The Role of Cartilage Oligomer Matrix Protein (COPM) in Diagnostics of Early Cartilage Destruction in Reactive Arthritis. Annals of the Romanian Society for Cell Biology; Arad Том 25, Изд. 1, (2021): 4404-4410.
9. Lambert E, Straznicky N, Eikelis N, et al. Sympathetic nervous system activity in obesity and metabolic syndrome. Hypertension. 2010;55(5):1271–1278.
10. Landsberg L. Insulin-mediated sympathetic stimulation in obesity-related hypertension. J Hypertens. 2001;19(3):523–528.
11. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804–1814.
12. Nilsson PM. Metabolic syndrome: epidemiology and strategies for cardiovascular risk reduction. Drugs. 2006;66(13):1741–1750.
13. Redon J, Grassi G. Impact of antihypertensive treatment on sympathetic nervous system activity. J Hypertens. 2012;30(5):937–943.
14. Rupp H, Jacob R. Metabolic effects of moxonidine. Cardiovasc Drugs Ther. 2001;15(4):341–346.
15. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12.
16. Williams B, Mancia G, Spiering W, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(6):873–980.
17. Ziegler D. Imidazoline receptor agonists in the treatment of hypertension. Drugs. 2004;64(5):421–432.
18. Абдурахманова, Наргиза и др. «Клиническое и диагностическое значение антител к CD74 у пациентов с анкилозирующим спондилитом среди населения Узбекистана». Журнал позитивной школьной психологии http://journalppw.com 6.6 (2022): 9358-9364.
19. АШ Ваисов, УА Ташкенбаева, М Рахимова. Состояние эндотелиальной функции у больных аллергическим васкулитом. OOO «Maxliyo-shifo» & V. 2012. 19.
20. Рахимова М.Б., Ходжиев С.Э., Разиков А.А., Рахимова М.Э. Оценка состояния гепатобилиарной зоны у больных с хроническими формами ИБС на фоне стандартного лечения. Медицина и здравоохранение : материалы VII Международной научной конференции (г. Краснодар, январь 2019 г.). Краснодар : Новация, 2019: 11–21
